A Phase 2 interventional study of NT 201 and NT 201 Placebo in Platysma Prominence, sponsored by Merz Aesthetics GmbH. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Merz Aesthetics GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety and efficacy of NT 201 in adults with moderate to severe platysma prominence.
Merz Aesthetics GmbH is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Dose 1.
Drug: NT 201
Subjects will receive Dose 2.
Drug: NT 201
Subjects will receive Dose 3.
Drug: NT 201
Subjects will receive matching placebo.
Drug: NT 201 Placebo
Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
Also known as: IncobotulinumtoxinA, Xeomin/Bocouture, Xeomin Cosmetic, Xeomeen
NT 201 Matching-placebo.
Change From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2
The platysma area was assessed live by the investigator at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.
Time frame: Baseline and Week 2
Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2
The platysma area was assessed live by the subject at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.
Time frame: Baseline and Week 2
Number of Subjects With Related Treatment Emergent Adverse Events (TEAEs)
TEAEs were defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment. An TEAE was considered to be "related" to IP(s) if a causal relationship between the IP(s) and an TEAE was at least a reasonable possibility (i.e., the relationship cannot be ruled out).
Time frame: From first dose of study drug up to Week 17
Subjects were recruited from 7 investigational sites in the United States.
| Milestone | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo |
|---|---|---|---|---|
| Started | 16 | 17 | 17 | 18 |
| Treated- safety evaluation set (ses) | 17 | 16 | 17 | 18 |
| Completed | 16 | 14 | 17 | 18 |
| Not completed | 0 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Subject relocated | 0 | 2 | 0 | 0 |
The platysma area was assessed live by the investigator at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.
| score on a scale | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo |
|---|---|---|---|---|
| Change From Baseline on the Merz Aesthetic Platysma Scale-Dynamic (MAPS-D) Score at Maximum Contraction as Assessed Live by the Investigator at Week 2 | -1.511 ± 0.1880 | -1.874 ± 0.1847 | -1.437 ± 0.1791 | -0.303 ± 0.1758 |
The platysma area was assessed live by the subject at maximum contraction and graded according to the validated five-point MAPS-D. Scores ranged from Grade 1 (none to minimal) to Grade 5 (very severe). The higher score indicated severe outcomes, and a negative change indicated improvements.
| score on a scale | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo |
|---|---|---|---|---|
| Change From Baseline on the MAPS-D Score at Maximum Contraction as Assessed by the Subject at Week 2 | -1.378 ± 0.2239 | -1.230 ± 0.2192 | -1.225 ± 0.2133 | -0.664 ± 0.2094 |
TEAEs were defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment. An TEAE was considered to be "related" to IP(s) if a causal relationship between the IP(s) and an TEAE was at least a reasonable possibility (i.e., the relationship cannot be ruled out).
| Participants | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo |
|---|---|---|---|---|
| Number of Subjects With Related Treatment Emergent Adverse Events (TEAEs) | 1 | 0 | 1 | 1 |
Collected over From the first dose of study drug up to Week 17. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Dose 1 NT201 | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
| Group 2: Dose 2 NT201 | 0/16 (0%) | 1/16 (6.3%) | 4/16 (25%) |
| Group 3: Dose 3 NT201 | 0/17 (0%) | 0/17 (0%) | 4/17 (23.5%) |
| Group 4: Placebo | 0/18 (0%) | 1/18 (5.6%) | 4/18 (22.2%) |
| Event | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo |
|---|---|---|---|---|
| CholecystitisHepatobiliary disorders | 0/17 | 1/16 | 0/17 | 0/18 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/17 | 0/16 | 0/17 | 1/18 |
| Event | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo |
|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 0/17 | 1/16 | 0/17 | 0/18 |
| Blood pressure diastolic increasedInvestigations | 0/17 | 1/16 | 0/17 | 0/18 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/17 | 1/16 | 0/17 | 0/18 |
| AnaemiaBlood and lymphatic system disorders | 0/17 | 1/16 | 0/17 | 0/18 |
| AnxietyPsychiatric disorders | 0/17 | 1/16 | 0/17 | 0/18 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/17 | 1/16 | 0/17 | 0/18 |
| Injection site bruisingGeneral disorders | 1/17 | 0/16 | 1/17 | 1/18 |
| Blood creatine phosphokinase increasedInvestigations | 0/17 | 0/16 | 1/17 | 0/18 |
| Gamma-glutamyltransferase increasedInvestigations | 1/17 | 0/16 | 0/17 | 0/18 |
| Lymphocyte count decreasedInvestigations | 1/17 | 0/16 | 0/17 | 0/18 |
The SES included all subjects who were exposed to investigational product (IP) at least once.
| Age, Continuous(years) | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo | Total |
|---|---|---|---|---|---|
| Mean | 51.2 ± 7.83 | 49.8 ± 8.71 | 49.9 ± 7.59 | 50.3 ± 6.86 | 50.3 ± 7.59 |
| Sex: Female, Male(Participants) | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo | Total |
|---|---|---|---|---|---|
| Female | 16 | 16 | 14 | 17 | 63 |
| Male | 1 | 0 | 3 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Group 1: Dose 1 NT201 | Group 2: Dose 2 NT201 | Group 3: Dose 3 NT201 | Group 4: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 0 | 4 |
| White | 14 | 15 | 15 | 16 | 60 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Oct 2023, 6 months.
Results were first posted in Nov 2026, 3 years after primary completion. A results delay was requested in Oct 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: incobotulinumtoxinA